Market Overview - The Shanghai Composite Index closed at 3683.46 points, above the six-month moving average, with an increase of 0.48% [1] - The total trading volume of A-shares reached 21,752.11 billion yuan [1] Stocks Breaking the Six-Month Moving Average - A total of 63 A-shares have surpassed the six-month moving average today [1] - Notable stocks with significant deviation rates include: - Guanggang Gas with a deviation rate of 10.02% - Fuan Energy at 9.12% - Tenglong Co. at 8.88% [1] Detailed Stock Performance - The following stocks showed notable performance: - Guanggang Gas: Today's increase of 13.13% with a turnover rate of 13.67% [1] - Fuan Energy: Increased by 10.04% with a turnover rate of 1.43% [1] - Tenglong Co.: Increased by 10.06% with a turnover rate of 7.65% [1] - Other stocks with smaller deviation rates include: - Guangshen Railway, Luopus Gold, and Chahua Co., which have just crossed the six-month line [1]

行 业 研 究 2025 年 08 月 08 日 投资评级：看好（维持） 行业走势图 -10% 0% 10% 19% 29% 38% 2024-08 2024-12 2025-04 2025-08 基础化工 沪深300 数据来源：聚源 相关研究报告 《中共中央政治局会议再度明确"反 内卷"决心，国家发改委将对内卷行 业展开摸底调查—化工行业周报》 -2025.8.3 《多国政策支持生物燃料行业发展， 行业景气度向上—行业点评报告》 -2025.8.1 《农药行业开展"正风治卷"三年行 动，看好供给优化助力盈利修复、景 气反转—行业点评报告》-2025.7.28 ——行业深度报告 氯碱盈利已触底，PVC 亏损严重，反内卷政策推动下行业盈利有望修复。2025 年 7 月 1 日，中央财经委员会第六次会议明确强调，依法依规治理企业低价无序竞 争，推动落后产能有序退出。从氯碱行业上市公司 2024 年利润情况看，在我们统计 的 14 家上市企业中，6 家企业的氯碱业务处于盈亏平衡或者亏损的状态，可能非上 市公司的情况更差。据我们测算，2025 年 7 月，片碱行业平均盈利约为 1,053 元/吨、 PVC 行业平均亏 ...

Summary of Key Points Core Viewpoint - The company, Inner Mongolia Junzheng Energy Chemical Group Co., Ltd., has announced the provision of guarantees for its subsidiaries, with a total expected guarantee amount of up to RMB 16.7 billion for the year 2025, which is within the approved limit by the shareholders' meeting [1][9]. Group 1: Guarantee Details - The company has provided a guarantee of RMB 200 million for its subsidiary, Ordos Junzheng Energy Chemical Co., Ltd., and RMB 100.8 million for another subsidiary, Junzheng Chemical [1][2]. - The total amount of guarantees provided by the company and its subsidiaries as of July 31, 2025, is RMB 1.7245 billion for Ordos Junzheng and RMB 3.2952 billion for Junzheng Chemical [1][2]. - The company has confirmed that there are no overdue guarantees as of the announcement date [1][10]. Group 2: Financial Metrics - The company’s total external guarantee amount is RMB 7.968 billion, which accounts for 29.25% of the latest audited net assets [9][10]. - The guarantees provided to subsidiaries total RMB 5.427 billion, representing 19.92% of the latest audited net assets [10]. - The guarantees among subsidiaries amount to RMB 2.541 billion, which is 9.33% of the latest audited net assets [10]. Group 3: Decision-Making Process - The board of directors approved the guarantee limits during meetings held on April 25 and May 16, 2025, with unanimous support [2][9]. - The expected guarantee limit is valid for 12 months from the date of approval by the shareholders' meeting [2][9]. - The board believes that the guarantees are necessary to support the operational needs of the subsidiaries and align with the company's overall interests and development strategy [8][9].

Core Viewpoint - Junzheng Group (601216) announced that the company has no overdue guarantees [1] Group 1 - The announcement was made on the evening of August 1 [1] - The company reassured stakeholders regarding its financial obligations [1]

证券代码：601216 证券简称：君正集团 公告编号：临 2025-024 号 担保 对象一 被担保人名称 鄂尔多斯市君正能源化工有限公司 （以下简称"鄂尔多斯君正"） 本次担保金额 20,000.00 万元 实际为其提供的担保余额 172,450.00 万元 是否在前期预计额度内 是 □否 □不适用：_________ 本次担保是否有反担保 □是 否 □不适用：_________ 担保 对象二 被担保人名称 内蒙古君正化工有限责任公司 （以下简称"君正化工"） 本次担保金额 10,080.00 万元 实际为其提供的担保余额 329,523.32 万元 是否在前期预计额度内 是 □否 □不适用：_________ 本次担保是否有反担保 □是 否 □不适用：_________ 关于 2025 年 7 月为子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 注：上述表中"实际为其提供的担保余额"为截至 2025 年 7 月 31 日公司及 控股子公司为其提供的担保余额数据。 ...

Core Viewpoint - The A-share market has seen a strong performance in the biopharmaceutical sector, particularly in vaccine stocks, driven by the release of the 2025 treatment plan for Chikungunya virus, highlighting the lack of available vaccines in China [1][2] Group 1: Market Performance - Shenyuan Biological (申联生物) rose by over 10%, with a year-to-date increase of 42.60% and a market capitalization of 3.203 billion [2] - Global Printing (环球印务) increased by 9.96%, with a market cap of 3.252 billion and a year-to-date rise of 34.04% [2] - Guanhao Biological (冠昊生物) saw a 7.70% increase, with a market cap of 4.969 billion and a year-to-date increase of 55.65% [2] - Sealy Medical (塞力医疗) rose by 5.60%, with a market cap of 6.055 billion and an impressive year-to-date increase of 339.06% [2] - Other notable performers include Kanglao Weishi (康乐卫士) up 4.98%, Jinhai Biological (金河生物) up 4.62%, and Weilan Biological (蔚蓝生物) up 4.41% [1][2] Group 2: Regulatory and Health Measures - The 2025 Chikungunya virus treatment plan emphasizes preventive measures such as eliminating mosquito breeding sites and using repellents [1] - Travelers to Chikungunya endemic areas are advised to enhance their preventive awareness to avoid infection [1] - Currently, there is no available vaccine for the Chikungunya virus in China, indicating a potential market opportunity for vaccine development [1]

Core Viewpoint - The A-share market has seen a strong performance in the biopharmaceutical sector, particularly in vaccine stocks, driven by the release of the 2025 treatment plan for Chikungunya virus, which has heightened awareness and demand for related medical solutions [1][2]. Group 1: Stock Performance - Shenyuan Biological (申联生物) rose by 10.33%, with a market capitalization of 3.203 billion [2] - Global Printing (环球印务) increased by 9.96%, with a market capitalization of 3.252 billion [2] - Guanhao Biological (冠昊生物) saw a rise of 7.70%, with a market capitalization of 4.969 billion [2] - Seer Medical (塞力医疗) grew by 5.60%, with a market capitalization of 6.055 billion [2] - Kanglao Guardian (康乐卫士) increased by 4.98%, with a market capitalization of 4.793 billion [2] - Jinhai Biological (金河生物) rose by 4.62%, with a market capitalization of 5.594 billion [2] - Weilan Biological (蔚蓝生物) increased by 4.41%, with a market capitalization of 3.831 billion [2] - Yongshun Biological (永顺生物) rose by 3.94%, with a market capitalization of 2.742 billion [2] - Dezhan Health (德展健康) increased by 3.51%, with a market capitalization of 10.5 billion [2] - Junzheng Group (君正集团) rose by 3.37%, with a market capitalization of 46.6 billion [2] - Kanghua Biological (康华生物) increased by 3.19%, with a market capitalization of 10.4 billion [2] Group 2: Market Context - The 2025 version of the Chikungunya virus treatment plan emphasizes preventive measures such as eliminating mosquito breeding grounds and using repellents [1] - There is currently no available vaccine for the Chikungunya virus in China, which may drive demand for vaccine development [1] - Free nucleic acid screening for Chikungunya virus is being conducted in Lecong Town, Shunde District, targeting close contacts of confirmed cases [1]

证券代码：601216 证券简称：君正集团 公告编号：临2025-023号 内蒙古君正能源化工集团股份有限公司 关于参加内蒙古辖区上市公司 2025 年投资者 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为进一步加强与投资者的互动交流，内蒙古君正能源化工集团股份有限公司 （以下简称"公司"）将参加由内蒙古证监局、内蒙古上市公司协会与深圳市全 景网络有限公司联合举办的"2025 年内蒙古辖区上市公司投资者网上集体接待 日活动"，现将本次活动的相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （https://rs.p5w.net），关注微信公众号"全景财经"，或下载全景路演 APP 参 与本次互动交流，活动时间为 2025 年 7 月 11 日（星期五）16:00-18:00。届时， 公司董事长、总经理乔振宇先生，独立董事郝银平先生，董事、副总经理杨东海 先生，财务总监范宇先生，董事会秘书吴婉贞女士将在线就公司 2024 年度业绩、 公司治理、发展战略、经营状况和可持续发展等投资者关心的问题 ...

Group 1: Core Business and Financial Performance - The core business of the company includes energy chemical and chemical logistics sectors, focusing on the manufacturing of chemical raw materials and products, as well as chemical logistics [1] - In Q1 2025, the company achieved a revenue of 6.206 billion yuan, representing a year-on-year growth of 19.39%, and a net profit attributable to shareholders of 946 million yuan, up 26.26% year-on-year [1] - As of March 31, 2025, the total assets of the company amounted to 43.3 billion yuan, an increase of 1.11% from the beginning of the year, while the equity attributable to shareholders rose by 3.83% to 28.281 billion yuan [1] Group 2: Digitalization and Technological Innovation - The company is focusing on digitalization and intelligentization to enhance process management and drive production innovation, which has become a consensus in the industry [3] - In 2024, the company identified "digitalization and intelligentization" as a key strategy for building new advantages, collaborating deeply with Huawei to create a comprehensive digital application and innovation model [3] - The goal is to develop a one-stop smart platform that integrates visualization, statistical analysis, early warning monitoring, predictive analytics, data quality management, and intelligent decision-making [3] Group 3: Research and Development - In 2024, the company's R&D investment reached 665 million yuan, accounting for 2.64% of sales revenue, with a workforce of 1,031 technology personnel [4] - As of December 31, 2024, the company held a total of 420 patents, including 45 invention patents, 374 utility model patents, and 1 design patent [4] - These achievements demonstrate the company's strong resilience and commitment to high-quality development, maintaining a high level of R&D investment and enhancing its role as a practitioner of innovation-driven development in the industry [4]

Group 1 - The electric carbide market is experiencing intense supply and demand dynamics, with prices showing volatility. On June 15, prices in the Wuhai region increased by 50 yuan per ton to 2400 yuan, but just two days later, on June 17, prices fell back to 2350 yuan due to weak price support and supply-demand battles [1] - Starting from June 13, the Inner Mongolia region implemented production limits due to electricity cost pressures, leading to a rapid contraction in supply, which initially supported price increases. However, several manufacturers have resumed production, significantly increasing market supply [2] - The demand side is showing weakness, particularly in the BDO industry, which is facing oversupply issues. It is projected that domestic BDO capacity will exceed 7 million tons by 2025, with utilization rates around 50%, severely limiting BDO's demand for electric carbide [3] Group 2 - The electric carbide market is currently in a phase of increasing supply, with several manufacturers resuming production and some downstream manufacturers undergoing maintenance, which has led to a passive increase in electric carbide supply [2] - There is a noticeable downward price linkage in the electric carbide market, driven by individual manufacturers' pricing strategies and the overall market dynamics. For instance, the Inner Mongolia Junzheng Chemical Company announced a price reduction of 50 yuan, prompting other manufacturers to follow suit [5][6] - The current market is also facing low raw material prices for Lantan, which has limited the cost support for electric carbide prices. The overall market sentiment suggests that the downward price trend may continue until a new equilibrium between supply, demand, and prices is established [7]